Abstract
Background: Mastocytosis is a clonal mast cell disorder characterized by chronic mediator‐related symptoms and heterogeneous systemic involvement. Neuropsychiatric symptoms are frequently reported, yet population‐based evidence on incident depression and/or anxiety remains limited. Objective: To examine the mental health burden among patients with mastocytosis. Methods: We conducted a population‐based matched cohort study using Danish health registers to evaluate incident, pharmacologically treated depression/anxiety among adult patients diagnosed with mastocytosis between 2005 and 2023. Patients were matched 1:5 with individuals from the general Danish population on age, sex, Charlson Comorbidity Index, and educational level. Individuals with psychotropic drug (PD) prescription within 10 years prior to index were excluded. Cumulative risks were estimated using the Aalen‐Johansen estimator, and hazard ratios (HRs) were calculated using Cox proportional hazard regression. Results: We included 874 patients with mastocytosis and 4370 comparators. Patients had a higher risk of incident PD prescription in the 10 years following diagnosis ( p < 0.001). The 5‐year cumulative risk was 13.1% in patients and 8.4% in comparators. The HR for incident PD use was 1.72 (95% confidence interval 1.38–2.15, p < 0.001). Results were consistent across sensitivity and landmark analyses. Higher age, comorbidity, and shorter education were associated with increased risk. Conclusion: Mastocytosis was associated with an increased risk of PD prescriptions, possibly reflecting an increased burden of pharmacologically treated depression and/or anxiety, implying the importance of mental health awareness in clinical management.
Funding Information
  • Aase og Ejnar Danielsens Fond

This publication has 48 references indexed in Scilit: